These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 21488050)

  • 1. Mannitol-guided delivery of Ciprofloxacin in artificial cystic fibrosis mucus model.
    Yang Y; Tsifansky MD; Shin S; Lin Q; Yeo Y
    Biotechnol Bioeng; 2011 Jun; 108(6):1441-9. PubMed ID: 21488050
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis.
    Yang Y; Tsifansky MD; Wu CJ; Yang HI; Schmidt G; Yeo Y
    Pharm Res; 2010 Jan; 27(1):151-60. PubMed ID: 19847626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.
    Adi H; Young PM; Chan HK; Agus H; Traini D
    Eur J Pharm Sci; 2010 Jun; 40(3):239-47. PubMed ID: 20371286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery of photosensitisers and light through mucus: investigations into the potential use of photodynamic therapy for treatment of Pseudomonas aeruginosa cystic fibrosis pulmonary infection.
    Donnelly RF; McCarron PA; Cassidy CM; Elborn JS; Tunney MM
    J Control Release; 2007 Feb; 117(2):217-26. PubMed ID: 17196290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gentamicin and leucine inhalable powder: what about antipseudomonal activity and permeation through cystic fibrosis mucus?
    Russo P; Stigliani M; Prota L; Auriemma G; Crescenzi C; Porta A; Aquino RP
    Int J Pharm; 2013 Jan; 440(2):250-5. PubMed ID: 22683456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Spray-drying of inhalable, multifunctional formulations for the treatment of biofilms formed in cystic fibrosis.
    Lababidi N; Ofosu Kissi E; Elgaher WAM; Sigal V; Haupenthal J; Schwarz BC; Hirsch AKH; Rades T; Schneider M
    J Control Release; 2019 Nov; 314():62-71. PubMed ID: 31654686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyanion-tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis.
    Craparo EF; Porsio B; Schillaci D; Cusimano MG; Spigolon D; Giammona G; Cavallaro G
    Nanomedicine (Lond); 2017 Jan; 12(1):25-42. PubMed ID: 27879162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Release of DNA from Pseudomonas aeruginosa in vitro during spontaneous growth and treatment with ciprofloxacin].
    Peng DZ; Guymon CH; McManus AT; Xiao GX
    Zhonghua Wai Ke Za Zhi; 2005 Feb; 43(3):178-81. PubMed ID: 15842899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections.
    Günday Türeli N; Torge A; Juntke J; Schwarz BC; Schneider-Daum N; Türeli AE; Lehr CM; Schneider M
    Eur J Pharm Biopharm; 2017 Aug; 117():363-371. PubMed ID: 28476373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors.
    Nafee N; Husari A; Maurer CK; Lu C; de Rossi C; Steinbach A; Hartmann RW; Lehr CM; Schneider M
    J Control Release; 2014 Oct; 192():131-40. PubMed ID: 24997276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new therapeutic avenue for bronchiectasis: Dry powder inhaler of ciprofloxacin nanoplex exhibits superior ex vivo mucus permeability and antibacterial efficacy to its native ciprofloxacin counterpart.
    Tran TT; Vidaillac C; Yu H; Yong VFL; Roizman D; Chandrasekaran R; Lim AYH; Low TB; Tan GL; Abisheganaden JA; Koh MS; Teo J; Chotirmall SH; Hadinoto K
    Int J Pharm; 2018 Aug; 547(1-2):368-376. PubMed ID: 29886096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ciprofloxacin-loaded lipid-core nanocapsules as mucus penetrating drug delivery system intended for the treatment of bacterial infections in cystic fibrosis.
    Torge A; Wagner S; Chaves PS; Oliveira EG; Guterres SS; Pohlmann AR; Titz A; Schneider M; Beck RCR
    Int J Pharm; 2017 Jul; 527(1-2):92-102. PubMed ID: 28499793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microparticles for inhalational delivery of antipseudomonal antibiotics.
    Tsifansky MD; Yeo Y; Evgenov OV; Bellas E; Benjamin J; Kohane DS
    AAPS J; 2008 Jun; 10(2):254-60. PubMed ID: 18454321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spray-freeze-dried liposomal ciprofloxacin powder for inhaled aerosol drug delivery.
    Sweeney LG; Wang Z; Loebenberg R; Wong JP; Lange CF; Finlay WH
    Int J Pharm; 2005 Nov; 305(1-2):180-5. PubMed ID: 16242277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A strategy to deliver genes to cystic fibrosis lungs: a battle with environment.
    Ibrahim BM; Park S; Han B; Yeo Y
    J Control Release; 2011 Oct; 155(2):289-95. PubMed ID: 21843562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming barriers in Pseudomonas aeruginosa lung infections: Engineered nanoparticles for local delivery of a cationic antimicrobial peptide.
    d'Angelo I; Casciaro B; Miro A; Quaglia F; Mangoni ML; Ungaro F
    Colloids Surf B Biointerfaces; 2015 Nov; 135():717-725. PubMed ID: 26340361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhalable DNase I microparticles engineered with biologically active excipients.
    Osman R; Al Jamal KT; Kan PL; Awad G; Mortada N; El-Shamy AE; Alpar O
    Pulm Pharmacol Ther; 2013 Dec; 26(6):700-9. PubMed ID: 23933140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
    Cantón R; Cobos N; de Gracia J; Baquero F; Honorato J; Gartner S; Alvarez A; Salcedo A; Oliver A; García-Quetglas E;
    Clin Microbiol Infect; 2005 Sep; 11(9):690-703. PubMed ID: 16104983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis.
    Guillot E; Sermet I; Ferroni A; Chhun S; Pons G; Zahar JR; Jullien V
    Pharmacotherapy; 2010 Dec; 30(12):1252-8. PubMed ID: 21114393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a dry, stable and inhalable acyl-homoserine-lactone-acylase powder formulation for the treatment of pulmonary Pseudomonas aeruginosa infections.
    Wahjudi M; Murugappan S; van Merkerk R; Eissens AC; Visser MR; Hinrichs WL; Quax WJ
    Eur J Pharm Sci; 2013 Mar; 48(4-5):637-43. PubMed ID: 23277289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.